Analyst Price Targets — PYPD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 17, 2025 3:00 pm | Boobalan Pachaiyappan | Roth Capital | $9.00 | $3.53 | TheFly | PolyPid price target lowered to $9 from $12 at Roth Capital |
| November 4, 2024 12:26 pm | Chase Knickerbocker | Craig-Hallum | $10.00 | $3.33 | StreetInsider | Craig-Hallum Starts PolyPid Ltd. (PYPD) at Buy |
Latest News for PYPD
PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in two upcoming investor conferences taking place during March 2026.
PolyPid (NASDAQ: PYPD) said 2025 marked a "pivotal year" as the company completed its SHIELD II Phase 3 trial and moved D-PLEX100 into the final stages of regulatory preparation, while also advancing U.S. commercial partnership discussions ahead of a planned new drug application submission in early 2026. Regulatory path: FDA supports rolling NDA submission Chief Executive
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
The Company is in Advanced Stage s of Commercial U.S. Partner ship Discussions for D-PLEX₁₀₀
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for PYPD.
Senate Trading
No Senate trades found for PYPD.
U.S. House Trading
No House trades found for PYPD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.